All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We asked, Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?
Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?
Perl reports the results from a retrospective study evaluating clinical outcomes in patients with relapsed or refractory AML treated with midostaurin or sorafenib before receiving gilteritinib in the CHRYSALIS trial and in the ADMIRAL trial.
Assoc. Prof. Tapan Kadia | ASH 2017 | New novel agents in AML
Assoc. Prof. Tapan Kadia | ASH 2017 | New novel agents in AML 59th ASH annual ASH Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Prof. Mark Levis | ASH 2017 | Overview of FLT3 inhibitors in AML
59th ASH Annual Meeting and Exposition, 9–12 Dec 2017, Atlanta, GA Professor Mark Levis The Johns Hopkins Hospital, Baltimore, USA Interview Title: Overview of FLT3 inhibitors in AML
Subscribe to get the best content related to AML delivered to your inbox